glp 1 mechanism of action diagram Schematic of GLP-1 on insulin secretion Frontiers | Exploring the multifaceted

Heat may affect the patchs performance

published in Diabetes, Obesity and Metabolism examined data from 52 randomized controlled trials involving over 75,000 participants treated with GLP-1 receptor agonists

Acknowledgements J.W., G.G.H., C.A.L

ChaudhuriAGhanimHVoraMSiaCLKorzeniewskiKDhindsaSet alExenatide exerts a potent antiinflammatory effect

Recommended starting dose: Discontinue other basal insulin and/or GLP-1 agonist before initiating Soliqua Patients naive to basal insulin or a GLP-1 agonist, currently on a GLP-1 agonist or less than 30 units of basal insulin daily: starting dose is 15 units once daily Patients currently on 30 to 60 units of basal insulin daily, with or without a GLP-1 agonist: starting dose is 30 units once daily Maintenance: titrate dose up or down by 2 - 4 units every week based on blood sugar goals Missed doses: resume dosing at the next scheduled dose

3.3 Mitochondrial dysfunction and oxidative stress Chronic hyperglycemia in patients with T2DM leads to peripheral insulin resistance, whereas impaired insulin signaling pathways in the brains of patients with AD lead to brain insulin resistance, both of which are closely related to mitochondrial dysfunction and OS (Zhang et al., 2023)